Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6150
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data ; volume:11 ; number:1 ; day:22 ; month:3 ; year:2016 ; pages:1-31 ; date:12.2016
Biology direct ; 11, Heft 1 (22.3.2016), 1-31, 12.2016
- Creator
-
Argyri, Katerina D.
- Contributor
-
Dionysiou, Dimitra D.
Misichroni, Fay D.
Stamatakos, Georgios S.
SpringerLink (Online service)
- DOI
-
10.1186/s13062-016-0114-9
- URN
-
urn:nbn:de:1111-2016032824337
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Argyri, Katerina D.
- Dionysiou, Dimitra D.
- Misichroni, Fay D.
- Stamatakos, Georgios S.
- SpringerLink (Online service)
Other Objects (12)
Antiangiogenic effects of oridonin
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
Antiangiogenic gene therapy of cancer: recent developments
Future options of anti-angiogenic cancer therapy
Antiangiogenic therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Anti-angiogenic effect of high doses of ascorbic acid
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Antiangiogenic effects of oridonin
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
Antiangiogenic gene therapy of cancer: recent developments
Future options of anti-angiogenic cancer therapy
Antiangiogenic therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Anti-angiogenic effect of high doses of ascorbic acid
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Antiangiogenic effects of oridonin
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
'Resources to Needs': A Paradigm for Addressing the Potentiality of the Urban Volume
Antiangiogenic gene therapy of cancer: recent developments
Future options of anti-angiogenic cancer therapy
Antiangiogenic therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Anti-angiogenic effect of high doses of ascorbic acid
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab